Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy.

Authors :: Agudo B
Díaz G
González-Lama Y
Source :: Journal of Crohn's & colitis [J Crohns Colitis] 2016 Dec; Vol. 10 (12), pp. 1453-1454. Date of Electronic Publication: 2016 May 23.
Publication Year :: 2016

Subjects :: Adalimumab adverse effects
Anti-Inflammatory Agents adverse effects
Antitubercular Agents therapeutic use
Humans
Isoniazid therapeutic use
Latent Tuberculosis diagnostic imaging
Latent Tuberculosis prevention & control
Male
Middle Aged
Tomography, X-Ray Computed
Adalimumab therapeutic use
Anti-Inflammatory Agents therapeutic use
Colitis, Ulcerative drug therapy
Latent Tuberculosis chemically induced
Tumor Necrosis Factor-alpha antagonists & inhibitors

Full Text Access

Tools